Abstract
Background and Objective Mucormycosis, a serious and rare fungal infection, has occurred concurrently in COVID-19 patients globally. Mucormycosis is associated with a high risk of all-cause mortality, with mortality depending on body site infected, fungus type, and the patient’s overall condition. This deadly fungal infection is quite difficult and expensive to treat. Therefore, this scoping review aims to map all the empirical evidence on the COVID-19 associated mucormycosis with a special focus on clinical presentation, treatment, and patient outcomes.
Methods The proposed scoping review will be developed by adhering to the JBI methodology for scoping reviews and will be reported as per the Preferred Reporting Items for Systematic Reviews and Meta-analyses for Scoping Reviews (PRISMA-ScR). A detailed search strategy has already been utilized to locate both published and unpublished studies. Literature search was carried out in three phases. PubMed, Scopus, Cochrane, Google scholar was searched. We will include all those studies which are presenting mucormycosis cases in COVID-19 positive patients. Data will be extracted in a pre-designed data extraction sheet and risk of bias will be assessed using JBI critical appraisal tool. The primary outcome will be to summarize the clinical presentation, treatment, and patient outcomes in COVID-19 associated mucormycosis. Data will be presented in tabular form.
OSF registration number osf.io/438sm
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Salman Hussain is supported from Operational Programme Research, Development and Education Project, Postdoc2MUNI (No. CZ.02.2.69/0.0/0.0/18_053/0016952); Miloslav Klugar, Abanoub Riad, Radim Ličenik and Jitka Klugarova are supported by the INTER-EXCELLENCE grant number LTC20031 Towards an International Network for Evidence-based Research in Clinical Health Research in the Czech Republic. The work of Abanoub Riad is also supported by Masaryk University grants MUNI/IGA/1543/2020 and MUNI/A/1608/2020.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB approval is exempted because this is a scoping review
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data that support the findings of this study are available from the corresponding author upon reasonable request.
